


Elliot Coulbeck, Jason Eames*

Tetrahedron: Asymmetry 19 (2008) 2223




De >98%; ee >98%
 $[\alpha]_D^{20} = +92.5$ (c 4.9, CHCl₃)
 Source of chirality: chiral pool
 Absolute configuration: (S,R)

C₁₈H₁₇NO₃
 (2S,4R)-3-(2-Phenylpropionyl)-4-phenyl-oxazolidin-2-one

Elliot Coulbeck, Jason Eames*

Tetrahedron: Asymmetry 19 (2008) 2223




De >98%; ee >98%
 $[\alpha]_D^{20} = +121.6$ (c 0.6, CHCl₃)
 Source of chirality: chiral pool
 Absolute configuration: (S,R)

C₁₉H₁₉NO₃
 (2S,4R)-3-[2-(4-Methylphenyl)propionyl]-4-phenyl-oxazolidin-2-one

Elliot Coulbeck, Jason Eames*

Tetrahedron: Asymmetry 19 (2008) 2223




De >98%; ee >98%
 $[\alpha]_D^{20} = +118.7$ (c 6.0, CHCl₃)
 Source of chirality: chiral pool
 Absolute configuration: (S,R)

C₂₂H₂₅NO₃
 (2S,4R)-3-[2-(4-Isobutylphenyl)propionyl]-4-phenyl-oxazolidin-2-one


Elliot Coulbeck, Jason Eames*

Tetrahedron: Asymmetry 19 (2008) 2223




De >98%; ee >98%
 $[\alpha]_D^{20} = +144.4$ (c 1.6, CHCl₃)
 Source of chirality: chiral pool
 Absolute configuration: (S,R)

C₁₈H₁₆ClNO₃
 (2S,4R)-3-[2-(4-Chlorophenyl)propionyl]-4-phenyl-oxazolidin-2-one




De >98%; ee >98%
 $[\alpha]_D^{20} = +77.4$ (c 4.0, CHCl₃)
 Source of chirality: chiral pool
 Absolute configuration: (S,R)

C₁₉H₁₉NO₃
 (2S,4R)-3-(2-Phenylbutanoyl)-4-phenyl-oxazolidin-2-one




De = 54%; ee >98%
 $[\alpha]_D^{20} = +1.3$ (c 3.0, CHCl₃)
 Source of chirality: chiral pool
 Absolute configuration: (S,R)

C₂₀H₂₁NO₃
 (2S,4R)-3-(2-Phenyl-3-methylbutanoyl)-4-phenyl-oxazolidin-2-one




De = 96%; ee >98%
 $[\alpha]_D^{20} = -255.1$ (c 3.4, CHCl₃)
 Source of chirality: chiral pool
 Absolute configuration: (R,S)

C₃₀H₂₅NO₃
 (2R,4S)-3-(2-Phenylpropionyl)-4,5,5-triphenyl-oxazolidin-2-one




De = 96%; ee >98%
 $[\alpha]_D^{20} = -258.6$ (c 2.4, CHCl₃)
 Source of chirality: chiral pool
 Absolute configuration: (R,S)

C₃₁H₂₇NO₃
 (2R,4S)-3-[2-(4-Methylphenyl)propionyl]-4,5,5-triphenyl-oxazolidin-2-one




De = 96%; ee >98%
 $[\alpha]_D^{20} = -306.7$ (c 4.4, CHCl₃)
 Source of chirality: chiral pool
 Absolute configuration: (R,S)

C₃₄H₃₃NO₃
 (2R,4S)-3-[2-(4-Isobutylphenyl)propionyl]-4,5,5-triphenyl-oxazolidin-2-one




De = 92%; ee >98%
 $[\alpha]_D^{20} = -296.2$ (c 3.4, CHCl₃)
 Source of chirality: chiral pool
 Absolute configuration: (R,S)

C₃₀H₂₄ClNO₃
 (2R,4S)-3-[2-(4-Chlorophenyl)propionyl]-4,5,5-triphenyl-oxazolidin-2-one




De = 94%; ee >98%
 $[\alpha]_D^{20} = -195.2$ (c 3.4, CHCl₃)
 Source of chirality: chiral pool
 Absolute configuration: (R,S)

C₃₁H₂₇NO₃
 (2R,4S)-3-(2-Phenylbutanoyl)-4,5,5-triphenyl-oxazolidin-2-one




De = 76%; ee >98%
 $[\alpha]_D^{20} = -270.9$ (c 2.6, CHCl₃)
 Source of chirality: chiral pool
 Absolute configuration: (R,S)

C₃₂H₂₉NO₃
 (2R,4S)-3-(2-Phenyl-3-methylbutanoyl)-4,5,5-triphenyl-oxazolidin-2-one




$C_{35}H_{29}NO_4$
(2S,4R)-3-[2-(6-Methoxynaphth-2-yl)-propionyl]-4,5,5-triphenyl-oxazolidin-2-one

De = 92%; ee >98%
 $[\alpha]_D^{20} = +302.5$ (c 1.2, CHCl₃)
 Source of chirality: chiral pool
 Absolute configuration: (S,R)




$C_{23}H_{21}NO_4$
(2S,4R)-3-[2-(6-Methoxynaphth-2-yl)-propionyl]-4-phenyl-oxazolidin-2-one

De = 98%; ee >98%
 $[\alpha]_D^{20} = +207.5$ (c 0.8, CHCl₃)
 Source of chirality: chiral pool
 Absolute configuration: (S,R)





$C_9H_{10}O_2$
(S)-2-Phenylpropionic acid

Ee >95%
 $[\alpha]_D^{20} = +71.7$ (c 1.0, CHCl₃)
 Source of chirality: resolution
 Absolute configuration: (S)



$C_{13}H_{27}Cl_2O_5PRe$
[OC-6-52-C]-Dichlorooxo{2,3-dimethyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaphospholan-2-yloxy)-butan-2-oxo}(pyridine)rhenium(V)

Ee = 100%
 $[\alpha]_D^{25} = +1380$ (c 0.05, CH₂Cl₂)
 Source of chirality: autocatalytic asymmetric synthesis
 Absolute configuration: C

 $C_{72}H_{122}NO_{34}$ *N*-(6^I-Deoxy-2^I,3^I-di-*O*-methyl-hexakis(2^{II-VII},3^{II-VII},6^{II-VII}-tri-*O*-methyl) cyclomaltoheptaose)-deca-3,5,7,9-tetraen-1-imine $[\alpha]_D^{20} = +10 (c 0.3, CHCl_3)$  $C_{15}H_{15}NO$


(-)-(1'S,2S,3S)-3-Phenyl-2-(1-phenylethyl)oxaziridine

Ee = 100%

 $[\alpha]_D^{21.0} = -61.1 (c 0.02, CHCl_3)$

Source of chirality: asymmetric induction

Absolute configuration: (1'S,2S,3S)

 $C_{15}H_{15}NO$


(+)-(1'S,2R,3R)-3-Phenyl-2-(1-phenylethyl)oxaziridine

Ee = 100%

 $[\alpha]_D^{21.0} = +81.5 (c 0.01, CHCl_3)$

Source of chirality: asymmetric induction

Absolute configuration: (1'S,2R,3R)

 $C_{15}H_{15}NO$

(+)-(1'R,2R,3R)-3-Phenyl-2-(1-phenylethyl)oxaziridine

Ee = 100%

 $[\alpha]_D^{21.0} = +60.2 (c 0.01, CHCl_3)$

Source of chirality: asymmetric induction


Absolute configuration: (1'R,2R,3R)

Ee = 100%

 $[\alpha]_D^{21.0} = -79.9$ (c 0.02, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,2S,3S)

C₁₅H₁₅NO


(-)-(1'R,2S,3S)-3-Phenyl-2-(1-phenylethyl)oxaziridine

Ee = 100%

 $[\alpha]_D^{21.3} = -55.0$ (c 0.02, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'S,2S,3S)

C₁₆H₁₇NO


(-)-(1'S,2S,3S)-2-(1-Phenylethyl)-3-p-tolyloxaziridine

Ee = 100%

 $[\alpha]_D^{21.3} = +60.1$ (c 0.01, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'S,2R,3R)

C₁₆H₁₇NO


(+)-(1'S,2R,3R)-2-(1-Phenylethyl)-3-p-tolyloxaziridine

Ee = 100%

 $[\alpha]_D^{21.3} = +56.7$ (c 0.03, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,2R,3R)

C₁₆H₁₇NO


(+)-(1'R,2R,3R)-2-(1-Phenylethyl)-3-p-tolyloxaziridine

Ee = 100%

 $[\alpha]_D^{21.3} = -61.1$ (c 0.01, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,2S,3S)

 $C_{16}H_{17}NO$


(-)-(1'R,2S,3S)-2-(1-Phenylethyl)-3-p-tolyloxaziridine

Ee = 100%

 $[\alpha]_D^{25.0} = -41.9$ (c 0.02, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'S,2S,3S)

 $C_{16}H_{17}NO_2$


(-)-(1'S,2S,3S)-3-(4-Methoxyphenyl)-2-(1-phenylethyl)oxaziridine

Ee = 100%

 $[\alpha]_D^{25.0} = +90.6$ (c 0.02, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'S,2R,3R)

 $C_{16}H_{17}NO_2$


(+)-(1'S,2R,3R)-3-(4-Methoxyphenyl)-2-(1-phenylethyl)oxaziridine

Ee = 100%


 $[\alpha]_D^{25.0} = +43.0$ (c 0.01, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,2R,3R)

 $C_{16}H_{17}NO_2$

(+)-(1'R,2R,3R)-3-(4-Methoxyphenyl)-2-(1-phenylethyl)oxaziridine




$C_{16}H_{17}NO_2$
 $(-)-(1'R,2S,3S)$ -3-(4-Methoxyphenyl)-2-(1-phenylethyl)oxaziridine

Ee = 100%

 $[\alpha]_D^{25.0} = -89.1$ (c 0.01, $CHCl_3$)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,2S,3S)




$C_{15}H_{14}ClNO$
 $(-)-(1'S,2S,3S)$ -3-(4-Chlorophenyl)-2-(1-phenylethyl)oxaziridine

Ee = 100%

 $[\alpha]_D^{22.1} = -44.1$ (c 0.01, $CHCl_3$)

Source of chirality: asymmetric induction

Absolute configuration: (1'S,2S,3S)




$C_{15}H_{14}ClNO$
 $(+)-(1'S,2R,3R)$ -3-(4-Chlorophenyl)-2-(1-phenylethyl)oxaziridine

Ee = 100%

 $[\alpha]_D^{22.1} = +97.3$ (c 0.01, $CHCl_3$)

Source of chirality: asymmetric induction

Absolute configuration: (1'S,2R,3R)




$C_{15}H_{14}ClNO$
 $(+)-(1'R,2R,3R)$ -3-(4-Chlorophenyl)-2-(1-phenylethyl)oxaziridine

Ee = 100%

 $[\alpha]_D^{22.1} = +44.6$ (c 0.01, $CHCl_3$)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,2R,3R)




$C_{15}H_{14}ClNO$
 $(-)-(1'R,2S,3S)-3-(4-Chlorophenyl)-2-(1-phenylethyl)oxaziridine$

Ee = 100%

 $[\alpha]_D^{22.1} = -96.1$ (c 0.01, $CHCl_3$)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,2S,3S)




$C_{14}H_{14}N_2O$
 $(-)-(1'S,2S,3S)-2-[2-(1-Phenylethyl)oxaziridin-3-yl]pyridine$

Ee = 100%

 $[\alpha]_D^{24.0} = -78.1$ (c 0.03, $CHCl_3$)

Source of chirality: asymmetric induction

Absolute configuration: (1'S,2S,3S)




$C_{14}H_{14}N_2O$
 $(+)-(1'S,2R,3R)-2-[2-(1-Phenylethyl)oxaziridin-3-yl]pyridine$

Ee = 100%

 $[\alpha]_D^{24.0} = +91.8$ (c 0.02, $CHCl_3$)

Source of chirality: asymmetric induction

Absolute configuration: (1'S,2R,3R)



$C_{14}H_{14}N_2O$
 $(+)-(1'R,2R,3R)-2-[2-(1-Phenylethyl)oxaziridin-3-yl]pyridine$

Ee = 100%

 $[\alpha]_D^{24.0} = +77.3$ (c 0.01, $CHCl_3$)

Source of chirality: asymmetric induction


Absolute configuration: (1'R,2R,3R)

Ee = 100%

 $[\alpha]_D^{24.0} = -92.2$ (c 0.02, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,2S,3S)

C₁₄H₁₄N₂O


(-)-(1'R,2S,3S)-2-[2-(1-Phenylethyl)oxaziridin-3-yl]pyridine

Ee = 100%

 $[\alpha]_D^{22.3} = -103.9$ (c 0.01, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'S,2S,3S)

C₁₄H₁₄N₂O


(-)-(1'S,2S,3S)-4-[2-(1-Phenylethyl)oxaziridin-3-yl]pyridine

Ee = 100%

 $[\alpha]_D^{22.3} = +37.4$ (c 0.01, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'S,2R,3R)

C₁₄H₁₄N₂O


(+)-(1'S,2R,3R)-4-[2-(1-Phenylethyl)oxaziridin-3-yl]pyridine

Ee = 100%

 $[\alpha]_D^{22.3} = +102.1$ (c 0.01, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,2R,3R)

C₁₄H₁₄N₂O


(+)-(1'R,2R,3R)-2-[2-(1-Phenylethyl)oxaziridin-3-yl]pyridine

Ee = 100%

 $[\alpha]_D^{22.3} = -38.1$ (c 0.01, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,2S,3S)

C₁₄H₁₄N₂O


(-)-(1'R,2S,3S)-4-[2-(1-Phenylethyl)oxaziridin-3-yl]pyridine

Ee = 100%

 $[\alpha]_D^{23.0} = -60.2$ (c 0.02, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'S,2S,3S)

C₁₃H₁₄N₂OS


(-)-(1'S,2S,3S)-4-Methyl-2-[2-(1-phenylethyl)oxaziridin-3-yl]thiazole

Ee = 100%

 $[\alpha]_D^{23.0} = +84.6$ (c 0.02, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'S,2R,3R)

C₁₃H₁₄N₂OS


(+)-(1'S,2R,3R)-4-Methyl-2-[2-(1-phenylethyl)oxaziridin-3-yl]thiazole

Ee = 100%



 $[\alpha]_D^{23.0} = +58.8$ (c 0.01, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,2R,3R)

C₁₃H₁₄N₂OS

(+)-(1'R,2R,3R)-4-Methyl-2-[2-(1-phenylethyl)oxaziridin-3-yl]thiazole





(-)-(1'R,2S,3S)-4-Methyl-2-[2-(1-phenylethyl)oxaziridin-3-yl]thiazole

Ee = 100%

 $[\alpha]_D^{23.0} = -84.1$ (c 0.01, $CHCl_3$)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,2S,3S)




(-)-(1'S,2S,3S)-2-[2-(1-Phenylethyl)oxaziridin-3-yl]benzothiazole

Ee = 100%

 $[\alpha]_D^{21.0} = -55.6$ (c 0.02, $CHCl_3$)

Source of chirality: asymmetric induction

Absolute configuration: (1'S,2S,3S)





(+)-(1'S,2R,3R)-2-[2-(1-Phenylethyl)oxaziridin-3-yl]benzothiazole

Ee = 100%

 $[\alpha]_D^{21.0} = +80.3$ (c 0.01, $CHCl_3$)

Source of chirality: asymmetric induction

Absolute configuration: (1'S,2R,3R)




(+)-(1'R,2R,3R)-2-[2-(1-Phenylethyl)oxaziridin-3-yl]benzothiazole

Ee = 100%

 $[\alpha]_D^{21.0} = +56.0$ (c 0.01, $CHCl_3$)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,2R,3R)




$C_{16}H_{14}N_2OS$
 $(-)-(1'R,2S,3S)-2-[2-(1-Phenylethyl)oxaziridin-3-yl]benzothiazole$

Ee = 100%

 $[\alpha]_D^{21.0} = -80.7$ (c 0.01, $CHCl_3$)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,2S,3S)




$C_{22}H_{22}N_2O$
 $(-)-(1'R,3R,5R)-(trans)-2-[3-Phenyl-2-(1-phenylethyl)isoxazolidin-5-yl]pyridine$

Ee = 100%

 $[\alpha]_D^{24.0} = -50.1$ (c 0.01, $CHCl_3$)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,3R,5R)




$C_{22}H_{22}N_2O$
 $(+)-(1'R,3R,5S)-(cis)-2-[3-Phenyl-2-(1-phenylethyl)isoxazolidin-5-yl]pyridine$

Ee = 100%

 $[\alpha]_D^{24.0} = +70.4$ (c 0.02, $CHCl_3$)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,3R,5S)




$C_{22}H_{22}N_2O$
 $(+)-(1'S,3S,5S)-(trans)-2-[3-Phenyl-2-(1-phenylethyl)isoxazolidin-5-yl]pyridine$

Ee = 100%

 $[\alpha]_D^{24.0} = +50.0$ (c 0.01, $CHCl_3$)

Source of chirality: asymmetric induction

Absolute configuration: (1'S,3S,5S)

C₂₂H₂₂N₂O


(-)-(1'S,3S,5R)-(cis)-2-[3-Phenyl-2-(1-phenylethyl)isoxazolidin-5-yl]pyridine

Ee = 100%

[α]_D^{24.0} = -70.2 (c 0.01, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'S,3S,5R)

C₂₂H₂₂N₂O


(+)-(1'R,3S,5S)-(trans)-2-[3-Phenyl-2-(1-phenylethyl)isoxazolidin-5-yl]pyridine

Ee = 100%

[α]_D^{24.0} = +21.2 (c 0.01, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,3S,5S)

C₂₂H₂₂N₂O


(-)-(1'R,3S,5R)-(cis)-2-[3-Phenyl-2-(1-phenylethyl)isoxazolidin-5-yl]pyridine

Ee = 100%

[α]_D^{24.0} = -26.0 (c 0.02, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,3S,5R)

C₂₂H₂₂N₂O


(-)-(1'S,3R,5R)-(trans)-2-[3-Phenyl-2-(1-phenylethyl)isoxazolidin-5-yl]pyridine

Ee = 100%

[α]_D^{24.0} = -21.0 (c 0.02, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'S,3R,5R)




C₂₂H₂₂N₂O
(+)-(1'S,3R,5S)-(cis)-2-[3-Phenyl-2-(1-phenylethyl)isoxazolidin-5-yl]pyridine

Ee = 100%

[α]_D^{24.0} = +26.3 (c 0.02, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'S,3R,5S)




C₂₃H₂₄N₂O₂
(-)-(1'R,3R,5R)-(trans)-2-[3-(4-Methoxyphenyl)-2-(1-phenylethyl)isoxazolidin-5-yl]pyridine

Ee = 100%

[α]_D^{21.0} = -55.3 (c 0.01, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,3R,5R)




C₂₃H₂₄N₂O₂
(-)-(1'S,3S,5R)-(cis)-2-[3-(4-Methoxyphenyl)-2-(1-phenylethyl)isoxazolidin-5-yl]pyridine

Ee = 100%

[α]_D^{21.0} = -65.6 (c 0.01, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'S,3S,5R)




C₂₃H₂₄N₂O₂
(+)-(1'S,3S,5S)-(trans)-2-[3-(4-Methoxyphenyl)-2-(1-phenylethyl)isoxazolidin-5-yl]pyridine

Ee = 100%

[α]_D^{21.0} = +55.1 (c 0.02, CHCl₃)


Source of chirality: asymmetric induction

Absolute configuration: (1'S,3S,5S)




Ee = 100%
 $[\alpha]_D^{21.0} = +64.9$ (c 0.01, CHCl₃)
 Source of chirality: asymmetric induction
 Absolute configuration: (1'R,3R,5S)

(+)-(1'R,3R,5S)-(cis)-2-[3-(4-Methoxyphenyl)-2-(1-phenylethyl)isoxazolidin-5-yl]pyridine




Ee = 100%
 $[\alpha]_D^{21.0} = -15.1$ (c 0.01, CHCl₃)
 Source of chirality: asymmetric induction
 Absolute configuration: (1'S,3R,5R)

(-)-(1'S,3R,5R)-(trans)-2-[3-(4-Methoxyphenyl)-2-(1-phenylethyl)isoxazolidin-5-yl]pyridine




Ee = 100%
 $[\alpha]_D^{21.0} = +30.3$ (c 0.01, CHCl₃)
 Source of chirality: asymmetric induction
 Absolute configuration: (1'S,3R,5S)

(+)-(1'S,3R,5S)-(cis)-2-[3-(4-Methoxyphenyl)-2-(1-phenylethyl)isoxazolidin-5-yl]pyridine



Ee = 100%
 $[\alpha]_D^{21.0} = +15.5$ (c 0.01, CHCl₃)
 Source of chirality: asymmetric induction
 Absolute configuration: (1'R,3S,5S)

(+)-(1'R,3S,5S)-(trans)-2-[3-(4-Methoxyphenyl)-2-(1-phenylethyl)isoxazolidin-5-yl]pyridine




(*-*)-(1'R,3S,5R)-(cis)-2-[3-(4-Methoxyphenyl)-2-(1-phenylethyl)isoxazolidin-5-yl]pyridine

Ee = 100%

$[\alpha]_D^{21.0} = -31.3$ (*c* 0.01, CHCl₃)

Source of chirality: asymmetric induction

Absolute configuration: (1'R,3S,5R)




C₂₀H₂₃NS
(*-*)-(1S,3R,4R)-2-Benzyl-3-phenylsulfanyl methyl-2-azabicyclo[2.2.1]heptane

$[\alpha]_D^{20} = -13.1$ (*c* 1.56, CH₂Cl₂) >95% ee

Source of chirality: chiral substrate

Absolute configuration: (S,R,R) (by chemical correlation)




C₂₁H₂₅NS
(*-*)-(1S,3R,4R)-2-[(S)-1-Phenylethyl]-3-phenylsulfanyl methyl-2-azabicyclo[2.2.1]heptane

$[\alpha]_D^{20} = -5.1$ (*c* 1.47, CH₂Cl₂) >95% ee

Source of chirality: chiral substrates

Absolute configuration: (S,R,R,S) (by chemical correlation)




C₂₀H₂₃NSe
(*-*)-(1S,3R,4R)-2-Benzyl-3-phenylselenanyl methyl-2-azabicyclo[2.2.1]heptane

$[\alpha]_D^{20} = -32.5$ (*c* 0.80, CH₂Cl₂) >95% ee

Source of chirality: chiral substrate

Absolute configuration: (S,R,R) (by chemical correlation)




$[\alpha]_D^{20} = -80.3$ (*c* 0.66, CH_2Cl_2) >95% ee

Source of chirality: chiral substrates

Absolute configuration: (S,R,R,S) (by chemical correlation)

$\text{C}_{21}\text{H}_{25}\text{NSE}$

(*-*)-(1*S*,3*R*,4*R*)-2-[(*S*)-1-Phenylethyl]-3-phenylselenalylmethyl-2-azabicyclo[2.2.1]heptane




$[\alpha]_D^{20} = -126.6$ (*c* 0.30, CH_2Cl_2) >95% ee

Source of chirality: chiral substrates

Absolute configuration: (S,R,R,S) (by chemical correlation)

$\text{C}_{30}\text{H}_{40}\text{N}_2\text{S}_2$

(*-*)-Bis-3-((1*S*,3*R*,4*R*)-2-[(*S*)-1-phenylethyl]-2-azabicyclo[2.2.1]heptane)methyl disulfide




$[\alpha]_D^{20} = -2.5$ (*c* 1.58, CH_2Cl_2) >95% e.e.

Source of chirality: chiral substrates

Absolute configuration: (S,R,R,S,S) (by chemical correlation)

$\text{C}_{23}\text{H}_{28}\text{N}_2$

(*-*)-(1*S*,3*R*,4*R*)-2-[(*S*)-1-Phenylethyl]-3-[(*S*)-1-phenylethylimine]methyl-2-azabicyclo[2.2.1]heptane




$[\alpha]_D^{20} = +52.9$ (*c* 0.44, CH_2Cl_2) >95% ee

Source of chirality: chiral substrates

Absolute configuration: (S,R,R,S,R) (by chemical correlation)

$\text{C}_{23}\text{H}_{28}\text{N}_2$

(*+*)-(1*S*,3*R*,4*R*)-2-[(*S*)-1-Phenylethyl]-3-[(*R*)-1-phenylethylimine]methyl-2-azabicyclo[2.2.1]heptane




$C_{18}H_{25}NS_2$
 $(+)-(1S,3R,4R)-2-[(S)-1-Phenylethyl]-3-(2-dithiane)-2-azabicyclo[2.2.1]heptane$

$[\alpha]_D^{20} = +18.4$ (c 0.68, CH_2Cl_2 , >95% ee)

Source of chirality: chiral substrate

Absolute configuration: (S,R,R,S) (by chemical correlation)




$C_{17}H_{23}NS_2$
 $(+)-(1S,3R,4R)-2-[(S)-1-Phenylethyl]-3-(2-dithiolate)-2-azabicyclo[2.2.1]heptane$

$[\alpha]_D^{20} = +3.4$ (c 0.74, CH_2Cl_2) >95% e.e.

Source of chirality: chiral substrate


Absolute configuration: (S,R,R,S) (by chemical correlation)



$C_{17}H_{34}N_4OS$
 $2-[3-(2\text{-Dimethylamino-cyclohexyl})\text{-thioureido}]\text{-}3,3,N,N\text{-tetramethyl-butyramide}$

Ee = 99%

$[\alpha]^{23} = +9.5$ (c 1.31, $CHCl_3$)




$C_{16}H_{32}N_4OS$
 $2-[3-(2\text{-Dimethylamino-cyclohexyl})\text{-thioureido}]\text{-}3,3,N\text{-trimethyl-butyramide}$



Ee = 99%

$[\alpha]^{23} = +1.5$ (c 1.01, $CHCl_3$)

Ee = 99%
 $[\alpha]^{23} = -6.5$ (c 1.06, CHCl₃)





N-Benzyl-2-[3-(2-dimethylamino-cyclohexyl)-thioureido]-3,3-dimethyl-butyramide





(S)-Methyl 2-(2-(R)-(2-acetamido-1-O-benzyl-4,6-O-benzylidene-2-deoxy-3-α-D-glucopyranosyloxy)propanamido)propanoate

Ee = 100%
 $[\alpha]^{20}_D = +44.6$ (c 0.21, DMF)
 Source of chirality: *N*-acetyl-*D*-glucosamine, asymmetric synthesis
 Absolute configuration: (S,R)




(S)-Methyl 2-(2-(R)-(2-acetamido-4,6-di-O-acetyl-1-O-benzyl-2-deoxy-3-α-D-glucopyranosyloxy)propanamido)propanoate

Ee = 100%
 $[\alpha]^{20}_D = +77.2$ (c 0.18, DMF)
 Source of chirality: *N*-acetyl-*D*-glucosamine, asymmetric synthesis
 Absolute configuration: (S,R)



(S)-Methyl 2-(2-(R)-(2-acetamido-2-deoxy-4,6-di-O-acetyl-1-O-diphenoxypyrophoryl-3-α-D-glucopyranosyloxy)propanamido)propanoate

Ee = 100%
 $[\alpha]^{20}_D = +61.4$ (c 0.22, DMF)
 Source of chirality: *N*-acetyl-*D*-glucosamine, asymmetric synthesis
 Absolute configuration: (S,R)




Ee = 100%

 $[\alpha]_D^{20} = +39.0$ (c 0.09, MeOH)Source of chirality: *N*-acetyl-D-glucosamine, asymmetric synthesis

Absolute configuration: (S,R)


Triethylammonium salt of (S)-methyl 2-(2-(R)-(2-acetamido-2-deoxy-4,6-di-O-acetyl-1-O-phosphoryl-3-α-D-glucopyranosyloxy)propanamido)propanoate




Ee = 100%

 $[\alpha]_D^{20} = +105.3$ (c 0.08, DMF)Source of chirality: *N*-acetyl-D-glucosamine, D-uridine, asymmetric synthesis

Absolute configuration: (S,R)




4-Morpholino-*N,N'*-dicyclohexylcarboxamidine salt of (S)-methyl 2-(2-(R)-(2-acetamido-2-deoxy-4,6-di-O-acetyl-1-O-(uridine-5'-diphosphoryl)-3-α-D-glucopyranosyloxy)propanamido)propanoate




Ee = 100%

 $[\alpha]_D^{20} = +40.7$ (c 0.04, MeOH)Source of chirality: *N*-acetyl-D-glucosamine, D-uridine, asymmetric synthesis

Absolute configuration: (S,R)



Trisodium (S)-2-(2-(R)-(2-acetamido-2-deoxy-1-O-(uridine-5'-diphosphoryl)-3-α-D-glucopyranosyloxy)propanamido)propanoate




(S)-2-(4'-Fluorophenylcarbamoyl)pyrrolidinium bromide

 $[\alpha]_D^{20} = -38.8$ (c 1.0, MeOH)

Source of chirality: L-proline


Absolute configuration: (S)

$[\alpha]_D^{20} = -36.4$ (c 1.0, MeOH)
 Source of chirality: L-proline
 Absolute configuration: (S)




$C_{11}H_{14}N_2OClBr$
 (S)-2-(4'-Chlorophenylcarbamoyl)pyrrolidinium bromide

$[\alpha]_D^{20} = -37.4$ (c 1.0, MeOH)
 Source of chirality: L-proline
 Absolute configuration: (S)




$C_{11}H_{14}N_2OBr_2$
 (S)-2-(4'-Bromophenylcarbamoyl)pyrrolidinium bromide

$[\alpha]_D^{20} = -36.3$ (c 0.71, MeOH)
 Source of chirality: L-proline
 Absolute configuration: (S)



$C_{11}H_{14}N_3O_3Br$
 (S)-2-(4'-Nitrophenylcarbamoyl)pyrrolidinium bromide

$[\alpha]_D^{20} = -38.1$ (c 0.94, MeOH)
 Source of chirality: L-proline
 Absolute configuration: (S)




$C_{11}H_{14}N_3O_3Br$
 (S)-2-(3'-Nitrophenylcarbamoyl)pyrrolidinium bromide

$[\alpha]_D^{20} = -29.7$ (c 0.21, MeOH)

Source of chirality: L-proline

Absolute configuration: (S)


 $C_{11}H_{14}N_3O_3Br$

(S)-2-(2'-Nitrophenylcarbamoyl)pyrrolidinium bromide

 $[\alpha]_D^{20} = -22.6$ (c 0.41, MeOH)

Source of chirality: L-proline

Absolute configuration: (S)


 $C_{16}H_{19}N_2OBr$

(S)-2-(1'-Naphthmethylcarbamoyl)pyrrolidinium bromide

 $[\alpha]_D^{20} = -22.4$ (c 0.49, MeOH)

Source of chirality: L-proline

Absolute configuration: (S)

 $C_{16}H_{19}N_2OBr$

(S)-2-(1'-Naphthmethylcarbamoyl)pyrrolidinium bromide

Ee = 100%

 $[\alpha]_D^{25} = +219.0$ (c 0.59, $CHCl_3$)


Source of chirality: enzymatic reduction

Absolute configuration: (1S,5S)

 $C_9H_{12}O_2$


(1S,5S)-Bicyclo[3.3.1]nonane-2,6-dione

$[\alpha]_D^{20} = -80.0$ (*c* 0.5, MeOH)
 Source of chirality: (1*R*)-(-)-myrtenal
 Absolute configuration: (1*R*,2*R*,5*S*,7*R*)




$C_{10}H_{15}NO$
 (1*R*,2*R*,5*S*,7*R*)-8,8-Dimethyl-3-azatricyclo[5.1.1.0^2.5]nonan-4-one

$[\alpha]_D^{20} = +4.8$ (*c* 0.5, MeOH)
 Source of chirality: (1*R*)-(-)-myrtenal
 Absolute configuration: (1*R*,2*R*,3*S*,5*R*)




$C_{11}H_{20}ClNO_2$
 Methyl (1*R*,2*R*,3*S*,5*R*)-2-amino-6,6-dimethylbicyclo[3.1.1]heptane-3-carboxylate hydrochloride

$[\alpha]_D^{20} = +23$ (*c* 0.5, MeOH)
 Source of chirality: (1*R*)-(-)-myrtenal
 Absolute configuration: (1*R*,2*R*,3*S*,5*R*)




$C_{12}H_{22}ClNO_2$
 Ethyl (1*R*,2*R*,3*S*,5*R*)-2-amino-6,6-dimethylbicyclo[3.1.1]heptane-3-carboxylate hydrochloride

$[\alpha]_D^{20} = +22.5$ (*c* 0.5, MeOH)
 Source of chirality: (1*R*)-(-)-myrtenal
 Absolute configuration: (1*R*,2*R*,3*S*,5*R*)




$C_{10}H_{18}ClNO_2$
 (1*R*,2*R*,3*S*,5*R*)-2-Amino-6,6-dimethylbicyclo[3.1.1]heptane-3-carboxylic acid hydrochloride

$[\alpha]_D^{20} = -1.6$ (c 0.5, MeOH)
 Source of chirality: (1R)-(-)-myrtenal
 Absolute configuration: (1R,2R,3S,5R)




$C_{10}H_{17}NO_2$
 (1R,2R,3S,5R)-2-Amino-6,6-dimethylbicyclo[3.1.1]heptane-3-carboxylic acid

$[\alpha]_D^{20} = -41.1$ (c 0.5, MeOH)
 Source of chirality: (1R)-(-)-myrtenal
 Absolute configuration: (1R,2R,5S,7R)




$C_{15}H_{23}NO_3$
 (1R,2R,5S,7R)-N-tert-Butoxycarbonyl-8,8-dimethyl-3-azatricyclo[5.1.1.0^2.5]nonan-4-one

$[\alpha]_D^{20} = +4.6$ (c 0.5, MeOH)
 Source of chirality: (1R)-(-)-myrtenal
 Absolute configuration: (1R,2R,3S,5R)




$C_{15}H_{25}NO_4$
 (1R,2R,3S,5R)-(2-tert-Butoxycarbonylamino)-6,6-dimethylbicyclo[3.1.1]heptane-3-carboxylic acid

$[\alpha]_D^{20} = +2$ (c 0.25, MeOH)
 Source of chirality: (1R)-(-)-myrtenal
 Absolute configuration: (1R,2R,3S,5R)




$C_{13}H_{23}NO_2$
 (1R,2R,3S,5R)-2-(9H-Fluoren-9-yl-methoxycarbonylamino)-6,6-dimethylbicyclo[3.1.1]heptane-3-carboxylic acid

$[\alpha]_D^{20} = +10.7$ (*c* 0.505, MeOH)
 Source of chirality: (1*R*)(*–*)-myrtenal
 Absolute configuration: (1*S*,2*S*,3*R*,5*S*)




$C_{12}H_{22}ClNO_2$
 (1*S*,2*S*,3*R*,5*S*)-2-Dimethylamino-6,6-dimethylbicyclo[3.1.1]heptane-3-carboxylic acid hydrochloride

$[\alpha]_D^{20} = -32.4$ (*c* 0.5, MeOH)
 Source of chirality: (1*R*)(*–*)-myrtenal
 Absolute configuration: (1*R*,2*R*,3*R*,5*R*)




$C_{12}H_{22}ClNO_2$
 Ethyl (1*R*,2*R*,3*R*,5*R*)-2-amino-6,6-dimethylbicyclo[3.1.1]heptane-3-carboxylate hydrochloride

$[\alpha]_D^{20} = -42.7$ (*c* 0.5, MeOH)
 Source of chirality: (1*R*)(*–*)-myrtenal
 Absolute configuration: (1*R*,2*R*,3*R*,5*R*)




$C_{10}H_{17}NO_2$
 (1*R*,2*R*,3*R*,5*R*)-2-Amino-6,6-dimethylbicyclo[3.1.1]heptane-3-carboxylic acid

$[\alpha]_D^{20} = -32.6$ (*c* 0.5, MeOH)
 Source of chirality: (1*R*)(*–*)-myrtenal
 Absolute configuration: (1*R*,2*R*,3*R*,5*R*)




$C_{10}H_{18}ClNO_2$
 (1*R*,2*R*,3*R*,5*R*)-2-Amino-6,6-dimethylbicyclo[3.1.1]heptane-3-carboxylic acid hydrochloride

$[\alpha]_D^{20} = -43.3$ (*c* 0.5, MeOH)
 Source of chirality: (1*R*)-(-)-myrtenal
 Absolute configuration: (1*R*,2*R*,3*R*,5*R*)




$C_{15}H_{25}NO_4$
 (1*R*,2*R*,3*R*,5*R*)-(2-*tert*-Butoxycarbonylamino)-6,6-dimethylbicyclo[3.1.1]heptane-3-carboxylic acid

$[\alpha]_D^{20} = -4$ (*c* 0.25, MeOH)
 Source of chirality: (1*R*)-(-)-myrtenal
 Absolute configuration: (1*R*,2*R*,3*R*,5*R*)




$C_{25}H_{27}NO_4$
 (1*R*,2*R*,3*R*,5*R*)-2-(9*H*-Fluoren-9-yl-methoxycarbonylamino)-6,6-dimethylbicyclo[3.1.1]heptane-3-carboxylic acid

$[\alpha]_D^{20} = +22.5$ (*c* 0.5, MeOH)
 Source of chirality: (1*R*)-(-)-myrtenal, (S)-phenylalanine
 Absolute configuration: (2*S*,1*R*,2*R*,3*S*,5*R*)




Ethyl (2*S*,1*R*,2*R*,3*S*,5*R*)-2-[(2'-*tert*-Butoxycarbonylamino)-6',6'-dimethylbicyclo[3.1.1]heptane-3'-carbonyl]amino-3-phenylpropionate

$[\alpha]_D^{20} = -15$ (*c* 0.25, MeOH)
 Source of chirality: (1*R*)-(-)-myrtenal, (S)-phenylalanine
 Absolute configuration: (2*S*,1*R*,2*R*,3*R*,5*R*)




Ethyl (2*S*,1*R*,2*R*,3*R*,5*R*)-2-[(2'-*tert*-Butoxycarbonylamino)-6',6'-dimethylbicyclo[3.1.1]heptane-3'-carbonyl]amino-3-phenylpropionate




$[\alpha]_D^{20} = -10$ (c 0.25, MeOH)
 Source of chirality: (1*R*)(-)-myrtenal, (S)-phenylalanine
 Absolute configuration: (2*S*,1'*S*,2'*S*,3'*R*,5'*S*)

Ethyl (2*S*,1'*S*,2'*S*,3'*R*,5'*S*)-2-[(2'-*tert*-butoxycarbonylamino)-6',6'-dimethylbicyclo[3.1.1]heptane-3'-carbonyl]amino-3-phenylpropionate




$[\alpha]_D^{20} = +18$ (c 0.25, MeOH)
 Source of chirality: (1*R*)(-)-myrtenal, (S)-phenylalanine
 Absolute configuration: (2*S*,1'*S*,2'*S*,3'*S*,5'*S*)

Ethyl (2*S*,1'*S*,2'*S*,3'*S*,5'*S*)-2-[(2'-*tert*-butoxycarbonylamino)-6',6'-dimethylbicyclo[3.1.1]heptane-3'-carbonyl]amino-3-phenylpropionate




Ee = 99%
 $[\alpha]_D^{21} = +27.1$ (c 1.44, CHCl₃)
 Source of chirality: pig liver esterase
 Absolute configuration: (R)

(R)-2-Methoxycarbonyl-2-(2-chloro-5-methoxyphenyl)propanoic acid




Ee = 99%
 $[\alpha]_D^{21} = -16.5$ (c 1.49, CHCl₃)
 Source of chirality: pig liver esterase
 Absolute configuration: (R)

(R)-Methyl 2-phenylcarbamoyl-2-(2-chloro-5-methoxyphenyl)propanoate




Ee = 99%
 $[\alpha]_D^{22} = +52.3$ (c 1.61, CHCl₃)
 Source of chirality: pig liver esterase
 Absolute configuration: (R)

C₁₂H₁₅ClO₄
 (R)-Methyl 2-(2-chloro-5-methoxyphenyl)-3-hydroxy-2-methylpropanoate




Ee = 99%
 $[\alpha]_D^{22} = +10.5$ (c 0.84, CHCl₃)
 Source of chirality: pig liver esterase
 Absolute configuration: (R)

C₁₄H₁₉ClO₅
 (R)-Methyl 2-(2-chloro-5-methoxyphenyl)-3-methoxymethoxy-2-methylpropanoate




Ee = 99%
 $[\alpha]_D^{24} = +10.9$ (c 1.92, CHCl₃)
 Source of chirality: pig liver esterase
 Absolute configuration: (R)

C₁₃H₁₇ClO₅
 (R)-2-(2-Chloro-5-methoxyphenyl)-3-methoxymethoxy-2-methylpropanoic acid




Ee = 99%
 $[\alpha]_D^{21} = -36.6$ (c 1.34, CHCl₃)
 Source of chirality: pig liver esterase
 Absolute configuration: (R)

C₁₃H₁₇NO₄
 (R)-5-Methoxy-3-methoxymethoxymethyl-3-methylindolin-2-one




(R)-5-Methoxy-3-methoxymethoxymethyl-1,3-dimethylindolin-2-one

Ee = 99%
 $[\alpha]_D^{26} = -47.3$ (c 1.32, CHCl₃)
 Source of chirality: pig liver esterase
 Absolute configuration: (R)




(R)-3-Hydroxymethyl-5-methoxy-1,3-dimethylindolin-2-one

Ee = 99%
 $[\alpha]_D^{26} = -15.7$ (c 0.84, CHCl₃)
 Source of chirality: pig liver esterase
 Absolute configuration: (R)




(S)-3-Iodomethyl-5-methoxy-1,3-dimethylindolin-2-one

Ee = 99%
 $[\alpha]_D^{28} = -17.3$ (c 1.35, CHCl₃)
 Source of chirality: pig liver esterase
 Absolute configuration: (S)




(S)-(5-Methoxy-1,3-dimethyl-2-oxoindolin-3-yl)acetonitrile


Ee = 99%
 $[\alpha]_D^{25} = +58.9$ (c 1.42, CHCl₃)
 Source of chirality: pig liver esterase
 Absolute configuration: (S)




$[\alpha]_D = +15.9$ (c 0.4, MeOH)
 Source of chirality: (1R,2R)-diaminocyclohexane
 Absolute configuration: (R,R)




(1R,2R)-*N,N'*-Bis((naphtalen-2-yl)methyl)cyclohexane-1,2-diamine



$[\alpha]_D = -33.0$ (c 0.2, MeOH)
 Source of chirality: (1R,2R)-diaminocyclohexane
 Absolute configuration: (R,R)




(1R,2R)-*N,N'*-Bis(2(octyloxy)benzyl)cyclohexane-1,2-diamine



$[\alpha]_D = -62$ (c 0.5, MeOH)
 Source of chirality: (1R,2R)-diaminocyclohexane
 Absolute configuration: (R,R)




(1R,2R)-*N,N'*-Bis(2chlorobenzyl)cyclohexane-1,2-diamine



$[\alpha]_D = -53$ (c 0.5, MeOH)
 Source of chirality: (1R,2R)-diaminocyclohexane
 Absolute configuration: (R,R)




(1R,2R)-*N,N'*-Bis(3-chlorobenzyl)cyclohexane-1,2-diamine




$[\alpha]_D = +10.9$ (*c* 1.6, CH_2Cl_2)
 Source of chirality: (1*R*,2*R*)-diaminocyclohexane
 Absolute configuration: (*R,R*)




(1*R*,2*R*)-*N,N'*-Bis(4-bromobenzyl)-*N,N'*-dimethylcyclohexane-1,2-diamine



$[\alpha]_D = +475$ (*c* 0.016, CH_2Cl_2)
 Source of chirality: (1*R*,2*R*)-diaminocyclohexane
 Absolute configuration: (*R,R*)




(1*R*,2*R*)-*N,N'*-Bis(4-chlorobenzyl)cyclohexane-1,2-diamine copper(II) acetate




$[\alpha]_D = -46.2$ (*c* 0.5, MeOH)
 Source of chirality: (1*R*,2*R*)-diaminocyclohexane
 Absolute configuration: (*R,R*)




(1*R*,2*R*)-*N,N'*-Bis(4-chlorobenzyl)cyclohexane-1,2-diamine



$[\alpha]_D = -36.2$ (*c* 0.9, EtOH)
 Source of chirality: (1*R*,2*R*)-diaminocyclohexane
 Absolute configuration: (*R,R*)




(1*R*,2*R*)-*N,N'*-Bis(2,6-dichlorobenzyl)cyclohexane-1,2-diamine



$[\alpha]_D = -43.9$ (c 0.5, MeOH)
 Source of chirality: (1*R*,2*R*)-diaminocyclohexane
 Absolute configuration: (*R,R*)




(1*R*,2*R*)-*N,N'*-Bis(2-bromobenzyl)cyclohexane-1,2-diamine





(-)-(6*S*)-8-Methyl γ -ionone

Ee = 99%
 $[\alpha]_D^{20} = -19.8$ (c 1, CHCl₃)
 Source of chirality: lipase-mediated resolution
 Absolute configuration: (6*S*)



(+)-(6*S*)-10-Methyl γ -ionone

Ee = 99%
 $[\alpha]_D^{20} = +18.7$ (c 1, CHCl₃)
 Source of chirality: lipase-mediated resolution
 Absolute configuration: (6*S*)




(-)-(4*R*,6*S*)-4-Acetoxy-8-methyl γ -ionone

Ee = 99% (chiral GC)
 $[\alpha]_D^{20} = -17.1$ (c 1.5, CHCl₃)
 Source of chirality: lipase-mediated resolution
 Absolute configuration: (4*R*,6*S*)

Ee = 99% (chiral GC)
 $[\alpha]_D^{20} = +27.1$ (c 1.7, CHCl₃)


Source of chirality: lipase-mediated resolution
 Absolute configuration: (4R,6S)



(+)-(4R,6S)-4-Acetoxy-10-methyl γ -ionone


Ee = 87%
 $[\alpha]_D^{20} = +32.6$ (c 1, CHCl₃)

Source of chirality: lipase-mediated resolution
 Absolute configuration: (4S,6R)




(+)-(4S,6R)-4-Hydroxy-8-methyl γ -ionone

Ee = 100%
 $[\alpha]_D^{20} = +69.2$ (c 0.9, CHCl₃)
 Source of chirality: (S)-1-phenylethylamine
 Absolute configuration: (3S,3aR,6aS,1'S)




C₁₈H₂₈NO₄P
 Diethyl (3S,3aR,6aS)-hexahydro-2-[(S)-1-phenylethyl]-2H-cyclopenta[d]isoxazol-3-yl-3-phosphonate

Ee = 100%
 $[\alpha]_D^{20} = -106.8$ (c 1.0, CHCl₃)
 Source of chirality: (S)-1-phenylethylamine
 Absolute configuration: (3R,3aS,6aR,1'S)



C₁₈H₂₈NO₄P
 Diethyl (3R,3aS,6aR)-hexahydro-2-[(S)-1-phenylethyl]-2H-cyclopenta[d]isoxazol-3-yl-3-phosphonate



Ee = 100%


 $[\alpha]_D^{20} = -17.1$ (c 1.2, CHCl₃)

Source of chirality: (S)-1-phenylethylamine

Absolute configuration: (3S,3aR,6aR,1'S)

C₁₇H₂₆NO₅P

Diethyl (3S,3aR,6aR)-hexahydro-2-[(S)-1-phenylethyl]furo[3,2-d]isoxazol-3-yl-3-phosphonate



Ee = 100%


 $[\alpha]_D^{20} = -91.5$ (c 1.3, CHCl₃)

Source of chirality: (S)-1-phenylethylamine

Absolute configuration: (3R,3aS,6aS,1'S)

C₁₇H₂₆NO₅P

Diethyl (3R,3aS,6aS)-hexahydro-2-[(S)-1-phenylethyl]furo[3,2-d]isoxazol-3-yl-3-phosphonate



Ee = 100%


 $[\alpha]_D^{20} = +98.8$ (c 1.0, CHCl₃)

Source of chirality: (S)-1-phenylethylamine

Absolute configuration: (2R,3R,3aS,6aR)

C₁₃H₂₄NO₅P

tert-Butyl (2R,3R,3aS,6aR)-2-ethoxy-2-oxo-cyclopenta[d](1,2-oxaphospholan-3-yl)carbamate


 $[\alpha]_D^{20} = +2.3$ (c 1.4, MeOH)

Source of chirality: (S)-l-lysine-HCl

Absolute configuration: (R)


C₆H₁₆C₁₂N₂

(R)-2-(Aminomethyl)piperidine dihydrochloride




$[\alpha]_D^{20} = -46.9$ (c 1.6, CHCl₃)
 Source of chirality: (S)-L-lysine-HCl
 Absolute configuration: (S)

C₄₁H₄₄N₂O₂
 (S)-benzyl 2,6-bis(dibenzylamino)hexanoate



$[\alpha]_D^{20} = +49.5$ (c 0.8, CHCl₃)
 Source of chirality: (S)-L-lysine-HCl
 Absolute configuration: (S)

C₃₄H₄₀N₂O
 (S)-2,6-Bis(dibenzylamino)hexan-1-ol



$[\alpha]_D^{20} = -73.5$ (c 1.1, CHCl₃)
 Source of chirality: (S)-L-lysine-HCl
 Absolute configuration: (R)

C₃₄H₃₉ClN₂
 (R)-1,1-Dibenzyl-2-((dibenzylamino)methyl)piperidinum chloride